BR112021026662A2 - Métodos para aliviar a preocupação associada à pterígio sobre a aparência do olho - Google Patents

Métodos para aliviar a preocupação associada à pterígio sobre a aparência do olho

Info

Publication number
BR112021026662A2
BR112021026662A2 BR112021026662A BR112021026662A BR112021026662A2 BR 112021026662 A2 BR112021026662 A2 BR 112021026662A2 BR 112021026662 A BR112021026662 A BR 112021026662A BR 112021026662 A BR112021026662 A BR 112021026662A BR 112021026662 A2 BR112021026662 A2 BR 112021026662A2
Authority
BR
Brazil
Prior art keywords
methods
eye
appearance
pterygium
alleviate
Prior art date
Application number
BR112021026662A
Other languages
English (en)
Portuguese (pt)
Inventor
Jinsong Ni
Rong Yang
Scott Whitcup
Original Assignee
Cloudbreak Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cloudbreak Therapeutics Llc filed Critical Cloudbreak Therapeutics Llc
Publication of BR112021026662A2 publication Critical patent/BR112021026662A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Eye Examination Apparatus (AREA)
BR112021026662A 2019-09-10 2020-09-10 Métodos para aliviar a preocupação associada à pterígio sobre a aparência do olho BR112021026662A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962898401P 2019-09-10 2019-09-10
PCT/US2020/050150 WO2021050692A2 (en) 2019-09-10 2020-09-10 Methods for alleviating pterygium-associated worry about eye appearance

Publications (1)

Publication Number Publication Date
BR112021026662A2 true BR112021026662A2 (pt) 2022-04-12

Family

ID=74870040

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021026662A BR112021026662A2 (pt) 2019-09-10 2020-09-10 Métodos para aliviar a preocupação associada à pterígio sobre a aparência do olho

Country Status (10)

Country Link
US (1) US20220331310A1 (cg-RX-API-DMAC10.html)
EP (1) EP4027997A4 (cg-RX-API-DMAC10.html)
JP (2) JP2022547401A (cg-RX-API-DMAC10.html)
KR (1) KR20220061147A (cg-RX-API-DMAC10.html)
CN (1) CN114340618A (cg-RX-API-DMAC10.html)
AU (2) AU2020346812A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021026662A2 (cg-RX-API-DMAC10.html)
CA (1) CA3146811A1 (cg-RX-API-DMAC10.html)
MX (1) MX2022000468A (cg-RX-API-DMAC10.html)
WO (1) WO2021050692A2 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108135737B (zh) 2015-06-06 2021-11-05 拨云生物医药科技(广州)有限公司 用于治疗翼状胬肉的组合物和方法
BR112018074450A2 (pt) 2016-06-02 2019-03-19 Cloudbreak Therapeutics, Llc composições e métodos para a utilização de nintedanib para melhorar o sucesso da cirurgia do glaucoma

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100185564A1 (en) * 2009-01-21 2010-07-22 Mccormick & Company, Inc. Method and questionnaire for measuring consumer emotions associated with products
WO2013188268A1 (en) * 2012-06-12 2013-12-19 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing pazopanib
US8747852B1 (en) * 2012-12-28 2014-06-10 Randal Tanh Hoang Pham Methods of treating pterygium
CN108135737B (zh) * 2015-06-06 2021-11-05 拨云生物医药科技(广州)有限公司 用于治疗翼状胬肉的组合物和方法
EA035465B1 (ru) * 2015-06-09 2020-06-22 Байер Фарма Акциенгезельшафт 7-замещенные 1-арил-нафтиридин-3-амиды карбоновой кислоты в качестве положительных аллостерических модуляторов мускаринового рецептора m2, способ их получения, их применение для лечения и/или профилактики заболеваний и лекарственное средство, содержащее эти соединения
TWI664965B (zh) * 2015-06-22 2019-07-11 新源生物科技股份有限公司 酪胺酸激酶抑制劑之眼用調配物、其使用方法、及其製備方法
CN108295072A (zh) * 2015-12-09 2018-07-20 瑞阳(苏州)生物科技有限公司 尼达尼布防治眼部疾病的用途
MX394623B (es) * 2016-02-04 2025-03-24 Ads Therapeutics Llc Tecnología de sinergismo anticuerpo-fármaco para el tratamiento de enfermedades.
BR112018074450A2 (pt) * 2016-06-02 2019-03-19 Cloudbreak Therapeutics, Llc composições e métodos para a utilização de nintedanib para melhorar o sucesso da cirurgia do glaucoma
US11278546B2 (en) * 2016-07-22 2022-03-22 Aiviva Biopharma, Inc. Multikinase inhibitors and uses in ocular fibrosis
WO2018064354A1 (en) * 2016-09-28 2018-04-05 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
JP7306697B2 (ja) * 2017-03-14 2023-07-11 オールジェネシス バイオセラピューティクス インコーポレイテッド ３－ｚ－［１－（４－（ｎ－（（４－メチル－ピペラジン－１－イル）－メチルカルボニル）－ｎ－メチル－アミノ）－フェニルアミノ）－１－フェニル－メチレン］－６－メトキシカルボニル－２－インドリノンの結晶形
KR20210013574A (ko) * 2018-05-25 2021-02-04 클라우드브레이크 테라퓨틱스, 엘엘씨 안구 충혈 치료용 조성물 및 이를 사용하여 안구 충혈을 치료하는 방법

Also Published As

Publication number Publication date
AU2020346812A1 (en) 2022-01-27
WO2021050692A3 (en) 2021-05-14
EP4027997A4 (en) 2023-10-11
MX2022000468A (es) 2022-02-03
KR20220061147A (ko) 2022-05-12
WO2021050692A2 (en) 2021-03-18
AU2026202351A1 (en) 2026-04-16
US20220331310A1 (en) 2022-10-20
CA3146811A1 (en) 2021-03-18
EP4027997A2 (en) 2022-07-20
JP2022547401A (ja) 2022-11-14
JP2026090631A (ja) 2026-06-02
CN114340618A (zh) 2022-04-12

Similar Documents

Publication Publication Date Title
JOP20200011B1 (ar) مركبات وتركيبات لمعالجة حالات مرضية مرتبطة بنشاط nlrp
DOP2019000241A (es) ANTICUERPOS ANTI-PÉPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
BR112022008641A2 (pt) Métodos de tratamento com modulador de miosina
ES3064032T3 (en) Ophthalmological compositions comprising brimonidine and ketotifen for use in the treatment of allergies
BR112016019592A8 (pt) Composto, uso de um composto, e, composição farmacêutica
BR112022003956A2 (pt) Anticorpos anti-cd73
BR112017009807A2 (pt) métodos e formulações para tratamento de doenças oculares vasculares
CL2017003436A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
MX392533B (es) Anticuerpos humanos contra glicoproteina del virus ebola.
MX389672B (es) Inhibidores de ssao de aminopirimidina
MX2017006823A (es) Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreina plasmatica.
UY34701A (es) Formas sólidas de un profármaco de nucleótidos de tiofosforamidato
BR112016000546A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
AR103130A1 (es) Sonda de vitrectomía con un escáner de fibra óptica
CU20170109A7 (es) Derivado de quinoleina para tratar y prevenir infecciones virales
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
BR112018013084A2 (pt) tratamentos de combinação compreendendo a administração de imidazopirazinonas
BR112015022650A2 (pt) inibidores de cinase induzível por sal macrocíclico
BR112018011851A2 (pt) compostos de isoindol
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
MX390536B (es) Composicion farmaceutica topica que comprende al menos amitriptilina para el tratamiento del dolor neuropatico periferico.
MX2020009532A (es) Oligonucleotidos modificados para uso en el tratamiento de tauopatias.
CO2022000270A2 (es) Inhibidores de enzimas
UY36099A (es) Laquinimod para el tratamiento de pacientes con esclerosis múltiple remitente recurrente (rrms) con un alto grado de discapacidad
BR112017002675A2 (pt) métodos para aperfeiçoar desempenho miocárdico em pacientes de fontan com o uso de composições de udenafila

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]